Physician profile
John Stephen Kellogg
NPI 1932149697
$16,972.34
in general payments reported to CMS, 2019-2025
45 companies · $4,087 in 2025
The $4,087 reported for 2025 was more than what 84% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,735 · 2021: $2,118 · 2022: $2,366 · 2023: $2,809 · 2024: $2,159 · 2025: $4,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,840 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,840.26 |
| Education | $215.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,139.61 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,951.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,480.56 | 2019-2025 | |
| Csl Behring | $1,195.05 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $933.33 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $721.35 | 2019-2025 | Dupixent |
| Pfizer INC. | $610.47 | 2019-2024 | |
| Amgen INC. | $565.97 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $482.56 | 2019-2025 | |
| Mylan Specialty L.P. | $354.31 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $347.37 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $340.73 | 2019-2022 | |
| Alk-Abello, INC | $291.10 | 2019-2023 | Odactra, Grastek |
| Optinose US, INC. | $282.63 | 2019-2025 | |
| Greer Laboratories, INC. | $266.31 | 2019-2024 | Oralair |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.